TobaccoReporter logo

Tag: pmi

  • Federal Judge Allows Deceptive Claim in Zyn Case

    Federal Judge Allows Deceptive Claim in Zyn Case

    A federal judge in Florida has allowed deceptive practices claims against Philip Morris International (PMI) and its subsidiaries to move forward, according to Law360. On December 12, U.S. District Judge William P. Dimitrouleas of the Southern District of Florida denied the companies’ motion to dismiss claims brought by plaintiff Kovadis Palmer under the Florida Deceptive and Unfair Trade Practices Act (FDUTPA).

    Palmer alleges that PMI and Swedish Match North America LLC misleadingly marketed Zyn nicotine pouches as “tobacco-free,” suggesting a lower addiction risk even though the nicotine is derived from tobacco. He claims he developed nicotine dependence as a result. While the court previously dismissed Palmer’s common-law fraud claims for failing to meet heightened pleading standards, it found that the amended FDUTPA claims advance a distinct legal theory.

    The judge ruled that FDUTPA claims do not require proof of intent to deceive and are not subject to the stricter fraud pleading rules. As a result, the court held that the claims are not merely a repackaging of dismissed fraud allegations and may proceed.

  • Tobacco Industry Alarmed at Bangladesh’s Policy-Making Exclusion

    Tobacco Industry Alarmed at Bangladesh’s Policy-Making Exclusion

    Bangladesh’s three largest tobacco companies—British American Tobacco, Philip Morris, and JT International—issued a rare joint statement criticizing the government’s move to advance amendments to the Tobacco Control Act without broad stakeholder consultation. The companies said several provisions in the draft ordinance are not evidence-based and would create “far-reaching, negative consequences” for the economy, tax revenue, foreign investment and millions of people connected to the industry.

    The firms argued that proposed ingredient bans would threaten cigarette production entirely, while new retail licensing requirements could disrupt sales for 1.5 million small retailers and impact the livelihoods of 150,000 tobacco farmers. They also warned that prohibiting smokeless nicotine and tobacco products would remove alternatives for adult consumers and likely expand an already growing illicit market, citing experiences in India and Australia.

    Industry leaders urged the government to re-engage manufacturers, farmers, retailers, and other affected groups, noting that previous reforms in 2005 succeeded because of inclusive dialogue. With tobacco tax revenue growth slowing and the sector supporting an estimated 4.4 million livelihoods, the companies called for a “balanced and comprehensive solution” to avoid unintended economic and public-health setbacks.

  • Tobacco Industry Alarmed at Bangladesh’s Policy-Making Exclusion

    In a unified statement, the industry leaders, British American Tobacco Bangladesh (BATB), Philip Morris Bangladesh, and JT International Bangladesh, said:
    “While we fully support the Government’s commitment to public health, we believe that the certain measures proposed in the draft ordinance are not evidence-based, and will jeopardize the local livelihoods, further fuel an already growing illicit tobacco market, result in government tax revenue leak, and discourage further foreign investment – ultimately severely impacting an already declining industry.

    “Amongst multiple detrimental clauses, the draft includes an ingredient ban, which poses direct threat to the current cigarette operations in the country entirely. The ingredients included in the proposal for ban are essential for processing, manufacturing, and preservation, and are critical to ensure product integrity. In addition, other business-critical clauses, such as mandating retailers license to sell cigarettes, will impact the current 1.5 million retailers and disrupt the legal sales of tobacco products to the retailers and the operations of associated 150,000 tobacco farmers, until the licenses are made available to all the impacted parties and this requires a fair and transparent process with proper consultation.

    “Furthermore, the proposed prohibition of smokeless nicotine and tobacco products will take away legitimate choices for adult nicotine consumers, who are looking for reduced risk profile alternatives compared to combustible cigarettes, to transition from combustible tobacco. A de-facto ban on these important product categories will further boost an existing illicit market with compromised quality products, as seen in other countries such as India and Australia. The illicit products will not be controlled by any standards to ensure product quality, further increasing the risk for consumer access to these products.”

    “Enacting the proposed Bill without a holistic stakeholder-inclusive consultation poses significant risks to Bangladesh’s economy and public health objectives. We urge the Government to consider the views of manufacturers, impacted farmers, marginalized retailers, hawkers, printers, and others in the value chain, to avoid the negative, unintended consequences caused by these proposed amendments. We are fully committed to collaborating with the Government, alongside other stakeholders, to find a balanced and comprehensive solution.”

  • Zyn Launches 1.5 Mg Option in UK

    Zyn Launches 1.5 Mg Option in UK

    Zyn launched Zyn X-Low, its lowest-strength nicotine pouch at 1.5mg, positioning it as an entry-level option for adult users new to the category, according to Talking Retail. The product expands Zyn’s UK and Ireland portfolio and is available in spearmint, black cherry, and cool mint via grocery, convenience, and wholesale channels, including Philip Morris’ Open retailer platform.

    “Expanding the range in this way allows us to meet a broader spectrum of adult nicotine preferences, strengthen the role of modern oral products in the marketplace, and further our ambition of achieving a smoke-free future,” said Dor Matot, head of Zyn UK and Ireland.

    The launch is backed by a nationwide marketing campaign aimed at highlighting strength choice and attracting first-time pouch users.

  • PMI Expands Partnership with Scuderia Ferrari HP

    PMI Expands Partnership with Scuderia Ferrari HP

    Philip Morris International announced an expanded partnership with Scuderia Ferrari HP and the Ferrari Challenge Trofeo Pirelli for the 2026 season and beyond. As part of the deal, PMI’s ZYN nicotine pouches will appear on select Scuderia Ferrari HP Formula 1 liveries, debuting at the Abu Dhabi Grand Prix on December 7.

    Stefano Volpetti, PMI’s President of Smoke-Free Products, said the collaboration reflects a shared drive to innovate and engage adult consumers. “By further enhancing our partnership with Scuderia Ferrari HP, we hope to accelerate the replacement of cigarettes, and we want our adult consumers of nicotine products, like ZYN, to embrace and enjoy every moment of this thrilling ride,” he said.

    Ferrari’s Lorenzo Giorgetti highlighted the partnership’s longevity and shared values, saying, “Our renewed collaboration with PMI continues a relationship that has lasted for over fifty years, grounded in scientific progress and long-term thinking.”

  • CEO Breaks Down PMI’s Smoke-free Future for Investors

    CEO Breaks Down PMI’s Smoke-free Future for Investors

    Philip Morris International used its appearance at the Morgan Stanley Global Consumer & Retail Conference yesterday (December 2) to reinforce that its smoke-free transition is a structural, irreversible shift, not a cyclical phase. CEO Jacek Olczak framed the dynamic succinctly, noting that smokers who switch to alternatives “very rarely” return to combustible cigarettes and that “smoke-free is essentially a one-way street.”

    Immediately before the event, PMI issued a brief communication to stabilize expectations, reaffirming the company’s guidance from Q3.

    Olczak said that PMI’s three-platform system—IQOS, ZYN, and vapor—is the most effective way to replace combustibles across all usage occasions. “Our objective is to equip the smoker with all three platforms. This is the best way to keep them away from smoking,” he said.

    ZYN remains PMI’s central U.S. growth engine. Following a one-time $100 million activation after supply shortages, “brand equity parameters of ZYN shot up by double-digits,” with the product capturing more than half of category growth despite maintaining a premium price.

    Internationally, IQOS is in its 11th consecutive year of expansion. Japan is nearing a 50/50 split between combustibles and smoke-free products, and prior category pauses were, Olczak said, “just a blip on the graph.” Upcoming Japanese tax equalization and European flavor bans are viewed as temporary disruptions rather than structural threats.

    PMI is also restructuring around a U.S./International dual-engine model, retiring its traditional regional setup. “We don’t really run the business by regions anymore,” Olczak said, positioning the company for future IQOS ILUMA authorization in the United States.

    Capital demands remain modest, with Olczak stressing that “adding extra capacity is only a few hundred million dollars — not a disturbing factor.” Overall, his message to investors was clear: the smoke-free shift is a one-way trajectory, and PMI believes it now has the platforms, structure, and regulatory environment to accelerate it.

  • Malaysia to Study Effects of IQOS

    Malaysia to Study Effects of IQOS

    Malaysia’s Home Ministry recommended that the National Poison Center conduct a study on IQOS, Philip Morris’ heated tobacco product. Minister Datuk Seri Saifuddin Nasution Ismail said the health effects of the device are not yet known, but an initial study would help prepare the government for future legislation. Speaking at a seminar, he described the product as a “new innovation posing regulatory challenges.” He emphasized that laws on poisons and drug abuse must remain dynamic to address emerging substances.

    Saifuddin added that while the device’s marketing campaign advises non-smokers not to start and encourages smokers to quit or switch, the government must be proactive in assessing potential risks. He suggested that legal amendments could be drafted broadly to prevent loopholes.

  • PMI CEO to Present at Morgan Stanley Conference

    PMI CEO to Present at Morgan Stanley Conference

    Philip Morris International Inc. announced it will host a live webcast of a fireside chat session with CEO Jacek Olczak at the 2025 Morgan Stanley Global Consumer & Retail Conference on December 2, at approximately 10:15 a.m. ET. An archived copy of the webcast will be available for six months post-event. The webcast can be accessed here, or on mobile devices by downloading PMI’s free Investor Relations Mobile App at www.pmi.com/irapp.

  • FDA Schedules TPSAC Review of ZYN Applications

    FDA Schedules TPSAC Review of ZYN Applications

    The U.S. Food and Drug Administration announced a January 22, 2026, virtual meeting of the Tobacco Products Scientific Advisory Committee (TPSAC) to review modified risk tobacco product (MRTP) applications submitted by Swedish Match USA for 20 ZYN nicotine pouch products. These products—already authorized for sale through the PMTA pathway in January 2025—include flavors such as Cool Mint, Citrus, Coffee, Peppermint, and Wintergreen, each in 3 mg and 6 mg strengths. The company is seeking permission to market the pouches with the claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

    Under federal law, MRTP applications must demonstrate that a product, as actually used by consumers, reduces individual health risks and benefits overall population health. TPSAC’s review will focus on scientific evidence regarding ZYN’s relative health risks, consumer comprehension of the proposed claim, and the potential public health impact of granting a modified risk order. The meeting will be held virtually, open to the public, captioned, and recorded.

    Public comments may be submitted to Docket No. FDA-2025-N-0835 through January 21, 2026, with comments received by January 7 provided directly to TPSAC. The FDA is also inviting individuals to request oral presentation slots during the meeting’s public comment period. Redacted MRTP application materials are available on the FDA’s website, and the agency will consider all public input and TPSAC recommendations before issuing a final decision.

  • PMI to Restructure Organization in 2026

    PMI to Restructure Organization in 2026

    Philip Morris International Inc. (PMI) further detailed its new organizational structure aimed at accelerating its transition to a smoke-free company. The changes establish two primary business units, PMI International and PMI U.S., along with its wellness unit, Aspeya, which will all report to CEO Jacek Olczak. The current four geographic segments will be replaced with three reportable segments: International Smoke-Free, International Combustibles, and U.S., with financial reporting under the new structure starting Q1 2026.

    First announced with its third-quarter financials, the changes will become effective January 1, 2026. Frederic de Wilde will serve as CEO of PMI International, and Stacey Kennedy will continue as CEO of PMI U.S.

    The restructuring reflects PMI’s focus on expanding smoke-free alternatives—which now account for 41% of the company’s net revenues—while maintaining growth in its combustibles business and exploring wellness and healthcare opportunities.